AccScience Publishing / BH / Online First / DOI: 10.36922/BH026260034
Submit to BH
Cite this article
17
Views
Related Info Links
Google Scholar
More by Authors Links
Junda Li
Journal Browser
Volume | Year
Issue
Search
Forthcoming Issue
Current Issue
View All
News and Announcements
View All
REVIEW ARTICLE

The neuropeptide Y–autonomic–cardiovascular axis in military traumatic stress: Molecular mechanisms and translational implications for brain–heart crosstalk

Jianda Kong1,2 ,  Junda Li3*
Show Less
1 College of Sports Science, Qufu Normal University, Qufu, Shandong, China
2 Shandong Provincial Key Laboratory of Physical Fitness and Health Promotion, College of Sports Science, Qufu Normal University, Qufu, Shandong, China
3 Unit 32128 of the People’s Liberation Army, China
Brain & Heart, 026260034 https://doi.org/10.36922/BH026260034
Received: 28 June 2026 | Revised: 1 August 2026 | Accepted: 7 August 2026 | Published online: 20 August 2026
© 2026 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )
Download PDF
XML
Cite
Abstract

Military traumatic stress provides a distinctive human model for studying brain–heart crosstalk because it combines threat exposure, operational strain, sleep disruption, autonomic activation, endocrine stress responses, and cardiovascular load. Posttraumatic stress disorder (PTSD) in military and veteran populations is increasingly recognized not only as a psychiatric consequence of trauma but also as a condition associated with elevated cardiovascular vulnerability. However, the molecular mechanisms linking traumatic stress, autonomic dysregulation, and cardiovascular risk remain insufficiently defined. Neuropeptide Y (NPY), a stress-responsive neuropeptide widely distributed throughout central and peripheral tissues, may represent a key molecular node in this process. Centrally, NPY participates in fear regulation, anxiety modulation, stress recovery, and resilience. Peripherally, NPY acts as a sympathetic co-transmitter and influences vascular tone, endothelial function, myocardial remodeling, and cardiac electrophysiology. This review summarizes evidence supporting the NPY–autonomic–cardiovascular axis as a mechanistic framework for brain–heart maladaptation in military traumatic stress. We propose a dual-role model in which acute stress-related NPY mobilization, interpreted alongside separate central-circuit evidence, may support resilience and preserve performance under extreme stress, whereas chronic NPY dysregulation or excessive peripheral sympathetic NPY signaling may contribute to autonomic imbalance, vascular dysfunction, arrhythmia susceptibility, and long-term cardiovascular burden. Translationally, NPY should not be treated as a stand-alone biomarker. Its value will depend on integration with heart rate variability, catecholamines, inflammatory markers, genetic variation, wearable monitoring, deployment exposure, PTSD trajectories, and cardiovascular endpoints. Future longitudinal military cohort studies are needed to determine whether NPY predicts risk, serves as a marker of recovery, mediates autonomic maladaptation, or identifies modifiable intervention targets in brain–heart medicine.

Keywords
Neuropeptide Y
Military traumatic stress
Posttraumatic stress disorder
Brain–heart crosstalk
Autonomic nervous system
Cardiovascular risk
Heart rate variability
Stress resilience
Funding
None.
Conflict of interest
The authors declare no conflicts of interest.
References
    1. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL. Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med. 2004;351(1):13-22. doi: 10.1056/NEJMoa040603
    2. Smith TC, Ryan MAK, Wingard DL, Slymen DJ, Sallis JF, Kritz-Silverstein D. New onset and persistent symptoms of post-traumatic stress disorder self reported after deployment and combat exposures: prospective population based US military cohort study. BMJ. 2008;336(7640):366-371. doi: 10.1136/bmj.39430.638241.AE
    3. Lieberman HR, Bathalon GP, Falco CM, Kramer FM, Morgan CA III, Niro P. Severe decrements in cognition function and mood induced by sleep loss, heat, dehydration, and undernutrition during simulated combat. Biol Psychiatry. 2005;57(4):422-429. doi: 10.1016/j.biopsych.2004.11.014
    4. Hines LA, Sundin J, Rona RJ, Wessely S, Fear NT. Posttraumatic stress disorder post Iraq and Afghanistan: prevalence among military subgroups. Can J Psychiatry. 2014;59(9):468-479. doi: 10.1177/070674371405900903
    5. Boscarino JA. A prospective study of PTSD and early-age heart disease mortality among Vietnam veterans: implications for surveillance and prevention. Psychosom Med. 2008;70(6):668-676. doi: 10.1097/PSY.0b013e31817bccaf
    6. Vaccarino V, Goldberg J, Rooks C, et al. Post-traumatic stress disorder and incidence of coronary heart disease: a twin study. J Am Coll Cardiol. 2013;62(11):970-978. doi: 10.1016/j.jacc.2013.04.085
    7. Ebrahimi R, Lynch KE, Beckham JC, et al. Association of posttraumatic stress disorder and incident ischemic heart disease in women veterans. JAMA Cardiol. 2021;6(6):642-651. doi: 10.1001/jamacardio.2021.0227
    8. Rosman L, Lampert R, Ramsey CM, et al. Posttraumatic stress disorder and risk for early incident atrial fibrillation: a prospective cohort study of 1.1 million young adults. J Am Heart Assoc. 2019;8(19):e013741. doi: 10.1161/JAHA.119.013741
    9. Rosman L, Sico JJ, Lampert R, et al. Posttraumatic stress disorder and risk for stroke in young and middle-aged adults: a 13-year cohort study. Stroke. 2019;50(11):2996-3003. doi: 10.1161/STROKEAHA.119.026854
    10. Buckley TC, Kaloupek DG. A meta-analytic examination of basal cardiovascular activity in posttraumatic stress disorder. Psychosom Med. 2001;63(4):585-594. doi: 10.1097/00006842-200107000-00011
    11. Pole N. The psychophysiology of posttraumatic stress disorder: a meta-analysis. Psychol Bull. 2007;133(5):725-746. doi: 10.1037/0033-2909.133.5.725
    12. Schneider M, Schwerdtfeger A. Autonomic dysfunction in posttraumatic stress disorder indexed by heart rate variability: a meta-analysis. Psychol Med. 2020;50(12):1937-1948. doi: 10.1017/S003329172000207X
    13. Minassian A, Maihofer AX, Baker DG, Nievergelt CM, Geyer MA, Risbrough VB. Association of predeployment heart rate variability with risk of postdeployment posttraumatic stress disorder in active-duty Marines. JAMA Psychiatry. 2015;72(10):979-986. doi: 10.1001/jamapsychiatry.2015.0922
    14. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci USA. 1982;79(18):5485-5489. doi: 10.1073/pnas.79.18.5485
    15. Dumont Y, Martel JC, Fournier A, St-Pierre S, Quirion R. Neuropeptide Y and neuropeptide Y receptor subtypes in brain and peripheral tissues. Prog Neurobiol. 1992;38(2):125-167. doi: 10.1016/0301-0082(92)90038-G
    16. Heilig M, McLeod S, Brot M, et al. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects. Neuropsychopharmacology. 1993;8(4):357-363. doi: 10.1038/npp.1993.35
    17. Lundberg JM, Torssell L, Sollevi A, et al. Neuropeptide Y and sympathetic vascular control in man. Regul Pept. 1985;13(1):41-52. doi: 10.1016/0167-0115(85)90085-0
    18. Warner MR, Senanayake PD, Ferrario CM, Levy MN. Sympathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart. Circ Res. 1991;69(2):455-465. doi: 10.1161/01.RES.69.2.455
    19. Morgan CA, Wang S, Southwick SM, et al. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol Psychiatry. 2000;47(10):902-909. doi: 10.1016/S0006-3223(99)00239-5
    20. Morgan CA, Wang S, Hazlett G, Rasmusson A, Anderson G, Charney DS. Relationship among cortisol, catecholamines, neuropeptide Y and human performance during exposure to uncontrollable stress. Psychosom Med. 2001;63(3):412-422. doi: 10.1097/00006842-200105000-00010
    21. Morgan CA, Rasmusson AM, Wang S, Hoyt G, Hauger RL, Hazlett G. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol Psychiatry. 2002;52(2):136-142. doi: 10.1016/S0006-3223(02)01319-7
    22. Rasmusson AM, Hauger RL, Morgan CA, Bremner JD, Charney DS, Southwick SM. Low baseline and yohimbine-stimulated plasma neuropeptide Y levels in combat-related PTSD. Biol Psychiatry. 2000;47(6):526-539. doi: 10.1016/S0006-3223(99)00185-7
    23. Sah R, Ekhator NN, Strawn JR, et al. Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol Psychiatry. 2009;66(7):705-707. doi: 10.1016/j.biopsych.2009.04.037
    24. Hoge CW, Auchterlonie JL, Milliken CS. Mental health problems, use of mental health services, and attrition from military service after returning from deployment to Iraq or Afghanistan. JAMA. 2006;295(9):1023-1032. doi: 10.1001/jama.295.9.1023
    25. Seelig AD, Jacobson IG, Smith B, et al. Sleep patterns before, during, and after deployment to Iraq and Afghanistan. Sleep. 2010;33(12):1615-1622. doi: 10.1093/sleep/33.12.1615
    26. Beristianos MH, Yaffe K, Cohen B, Byers AL. PTSD and risk of incident cardiovascular disease in aging veterans. Am J Geriatr Psychiatry. 2016;24(3):192-200. doi: 10.1016/j.jagp.2014.12.003
    27. Shah AJ, Lampert R, Goldberg J, Veledar E, Bremner JD, Vaccarino V. Posttraumatic stress disorder and impaired autonomic modulation in male twins. Biol Psychiatry. 2013;73(11):1103-1110. doi: 10.1016/j.biopsych.2013.01.019
    28. Minassian A, Geyer MA, Baker DG, Nievergelt CM, O’Connor DT, Risbrough VB. Heart rate variability characteristics in a large group of active-duty Marines and relationship to posttraumatic stress. Psychosom Med. 2014;76(4):292-301. doi: 10.1097/PSY.0000000000000056
    29. Naveilhan P, Neveu I, Arenas E, Ernfors P. Complementary and overlapping expression of Y1, Y2 and Y5 receptors in the developing and adult mouse nervous system. Neuroscience. 1998;87(1):289-302. doi: 10.1016/S0306-4522(98)00141-9
    30. Parker RM, Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci. 1999;11(4):1431-1448. doi: 10.1046/j.1460-9568.1999.00553.x
    31. Brothers SP, Wahlestedt C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol Med. 2010;2(11):429-439. doi: 10.1002/emmm.201000100
    32. Pedragosa-Badia X, Stichel J, Beck-Sickinger AG. Neuropeptide Y receptors: how to get subtype selectivity. Front Endocrinol. 2013;4:5. doi: 10.3389/fendo.2013.00005
    33. Kask A, Harro J, von Hörsten S, Redrobe JP, Dumont Y, Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci Biobehav Rev. 2002;26(3):259-283. doi: 10.1016/S0149-7634(01)00066-5
    34. Sajdyk TJ, Schober DA, Smiley DL, Gehlert DR. Neuropeptide Y-Y2 receptors mediate anxiety in the amygdala. Pharmacol Biochem Behav. 2002;71(3):419-423. doi: 10.1016/S0091-3057(01)00679-7
    35. Tasan RO, Nguyen NK, Weger S, et al. The central and basolateral amygdala are critical sites of neuropeptide Y/Y2 receptor-mediated regulation of anxiety and depression. J Neurosci. 2010;30(18):6282-6290. doi: 10.1523/JNEUROSCI.0430-10.2010
    36. Cohen H, Liu T, Kozlovsky N, Kaplan Z, Zohar J, Mathé AA. The neuropeptide Y (NPY)-ergic system is associated with behavioral resilience to stress exposure in an animal model of post-traumatic stress disorder. Neuropsychopharmacology. 2012;37(2):350-363. doi: 10.1038/npp.2011.230
    37. Gutman AR, Yang Y, Ressler KJ, Davis M. The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J Neurosci. 2008;28(48):12682-12690. doi: 10.1523/JNEUROSCI.2305-08.2008
    38. Fendt M, Bürki H, Imobersteg S, et al. Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect. Psychopharmacology. 2009;206(2):291-301. doi: 10.1007/s00213-009-1610-8
    39. Sah R, Geracioti TD. Neuropeptide Y and posttraumatic stress disorder. Mol Psychiatry. 2013;18(6):646-655. doi: 10.1038/mp.2012.101
    40. Morris MJ, Russell AE, Kapoor V, et al. Increases in plasma neuropeptide Y concentrations during sympathetic activation in man. J Auton Nerv Syst. 1986;17(2):143-149. doi: 10.1016/0165-1838(86)90089-5
    41. Schwertfeger E, Klein T, Vonend O, Oberhauser V, Stegbauer J, Rump LC. Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004;369(5):455-461. doi: 10.1007/s00210-004-0930-9
    42. Abdel-Samad D, Jacques D, Perreault C, Provost C. NPY regulates human endocardial endothelial cell function. Peptides. 2007;28(2):281-287. doi: 10.1016/j.peptides.2006.09.028
    43. Tan CMJ, Green P, Tapoulal N, Lewandowski AJ, Leeson P, Herring N. The role of neuropeptide Y in cardiovascular health and disease. Front Physiol. 2018;9:1281. doi: 10.3389/fphys.2018.01281
    44. Kalla M, Hao G, Tapoulal N, et al. The cardiac sympathetic co-transmitter neuropeptide Y is pro-arrhythmic following ST-elevation myocardial infarction despite beta-blockade. Eur Heart J. 2020;41(23):2168-2179. doi: 10.1093/eurheartj/ehz852
    45. Ajijola OA, Chatterjee NA, Gonzales MJ, et al. Coronary sinus neuropeptide Y levels and adverse outcomes in patients with stable chronic heart failure. JAMA Cardiol. 2020;5(3):318-325. doi: 10.1001/jamacardio.2019.4717
    46. Gibbs T, Tapoulal N, Fellows R, et al. Neuropeptide-Y levels in ST-segment-elevation myocardial infarction: relationship with coronary microvascular function, heart failure, and mortality. J Am Heart Assoc. 2022;11(13):e024850. doi: 10.1161/JAHA.121.024850
    47. Morgan CA, Wang S, Mason J, et al. Hormone profiles in humans experiencing military survival training. Biol Psychiatry. 2000;47(10):891-901. doi: 10.1016/S0006-3223(99)00307-8
    48. Szivak TK, Lee EC, Saenz C, et al. Adrenal stress and physical performance during military survival training. Aerosp Med Hum Perform. 2018;89(2):99-107. doi: 10.3357/AMHP.4831.2018
    49. Taylor MK, Sausen KP, Potterat EG, et al. Stressful military training: endocrine reactivity, performance, and psychological impact. Aviat Space Environ Med. 2007;78(12):1143-1149. doi: 10.3357/ASEM.2151.2007
    50. Morgan CA, Southwick S, Hazlett G, et al. Relationships among plasma dehydroepiandrosterone sulfate and cortisol levels, symptoms of dissociation, and objective performance in humans exposed to acute stress. Arch Gen Psychiatry. 2004;61(8):819-825. doi: 10.1001/archpsyc.61.8.819
    51. Morgan CA, Rasmusson AM, Winters B, et al. Trauma exposure rather than posttraumatic stress disorder is associated with reduced baseline plasma neuropeptide-Y levels. Biol Psychiatry. 2003;54(10):1087-1091. doi: 10.1016/S0006-3223(03)00433-5
    52. Yehuda R, Brand S, Yang RK. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol Psychiatry. 2006;59(7):660-663. doi: 10.1016/j.biopsych.2005.08.027
    53. Sah R, Ekhator NN, Jefferson-Wilson L, Horn PS, Geracioti TD Jr. Cerebrospinal fluid neuropeptide Y in combat veterans with and without posttraumatic stress disorder. Psychoneuroendocrinology. 2014;40:277-283. doi: 10.1016/j.psyneuen.2013.10.017
    54. Reijnen A, Geuze E, Eekhout I, et al. Biological profiling of plasma neuropeptide Y in relation to posttraumatic stress symptoms in two combat cohorts. Biol Psychol. 2018;134:72-79. doi: 10.1016/j.biopsycho.2018.02.008
    55. Kastin AJ, Akerstrom V. Nonsaturable entry of neuropeptide Y into brain. Am J Physiol Endocrinol Metab. 1999;276(3):E479-E482. doi: 10.1152/ajpendo.1999.276.3.E479
    56. Pernow J, Lundberg JM, Kaijser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci. 1987;40(1):47-54. doi: 10.1016/0024-3205(87)90251-7
    57. Sher L, Bierer LM, Flory J, Makotkine I, Yehuda R. Neuropeptide Y plasma levels and suicidal behavior in combat veterans. Eur Neuropsychopharmacol. 2020;40:31-37. doi: 10.1016/j.euroneuro.2020.06.003
    58. Tural U, Iosifescu DV. Neuropeptide Y in PTSD, MDD, and chronic stress: a systematic review and meta-analysis. J Neurosci Res. 2020;98(5):950-963. doi: 10.1002/jnr.24589
    59. Clarke JG, Davies GJ, Kerwin R, et al. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet. 1987;1(8541):1057-1059. doi: 10.1016/S0140-6736(87)90483-1
    60. Herring N, Tapoulal N, Kalla M, et al. Neuropeptide-Y causes coronary microvascular constriction and is associated with reduced ejection fraction following ST-elevation myocardial infarction. Eur Heart J. 2019;40(24):1920-1929. doi: 10.1093/eurheartj/ehz115
    61. Cuculi F, Herring N, De Caterina AR, et al. Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction. Heart. 2013;99(16):1198-1203. doi: 10.1136/heartjnl-2012-303443
    62. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res. 1998;83(2):187-195. doi: 10.1161/01.RES.83.2.187
    63. Lee EW, Michalkiewicz M, Kitlinska J, et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest. 2003;111(12):1853-1862. doi: 10.1172/JCI16929
    64. Zhang P, Qi YX, Yao QP, et al. Neuropeptide Y stimulates proliferation and migration of vascular smooth muscle cells from pregnancy hypertensive rats via Y1 and Y5 receptors. PLoS ONE. 2015;10(7):e0131124. doi: 10.1371/journal.pone.0131124
    65. Shah SH, Freedman NJ, Zhang L, et al. Neuropeptide Y gene polymorphisms confer risk of early-onset atherosclerosis. PLoS Genet. 2009;5(1):e1000318. doi: 10.1371/journal.pgen.1000318
    66. McDowell K, Graham J, Herring N, et al. Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. Eur J Heart Fail. 2024;26(1):107-116. doi: 10.1002/ejhf.3085
    67. Serova LI, Tillinger A, Alaluf LG, Laukova M, Keegan K, Sabban EL. Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats. Neuroscience. 2013;236:298-312. doi: 10.1016/j.neuroscience.2013.01.040
    68. Serova LI, Laukova M, Alaluf LG, Pucillo L, Sabban EL. Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model. Eur Neuropsychopharmacol. 2014;24(1):142-147. doi: 10.1016/j.euroneuro.2013.11.007
    69. Sayed S, Van Dam NT, Horn SR, et al. A randomized dose-ranging study of neuropeptide Y in patients with posttraumatic stress disorder. Int J Neuropsychopharmacol. 2018;21(1):3-11. doi: 10.1093/ijnp/pyx109
    70. Nahvi RJ, Tanelian A, Nwokafor C, Hollander CM, Peacock L, Sabban EL. Intranasal neuropeptide Y as a potential therapeutic for depressive behavior in the rodent single prolonged stress model in females. Front Behav Neurosci. 2021;15:705579. doi: 10.3389/fnbeh.2021.705579
    71. Wong CYJ, Baldelli A, Tietz O, et al. An overview of in vitro and in vivo techniques for characterization of intranasal protein and peptide formulations for brain targeting. Int J Pharm. 2024;654:123922. doi: 10.1016/j.ijpharm.2024.123922
    72. Lacroix JS, Ricchetti AP, Morel D, Mossimann B, Waeber B, Grouzmann E. Intranasal administration of neuropeptide Y in man: systemic absorption and functional effects. Br J Pharmacol. 1996;118(8):2079-2084. doi: 10.1111/j.1476-5381.1996.tb15647.x
    73. Sabban EL, Serova L, Nahvi RJ, Liu X. Potential benefits of intranasal neuropeptide Y include sustained extinction of fear memory. J Neuroendocrinol. 2023;35(11):e13279. doi: 10.1111/jne.13279
    74. Nahvi RJ, Sabban EL. Sex differences in the neuropeptide Y system and implications for stress-related disorders. Biomolecules. 2020;10(9):1248. doi: 10.3390/biom10091248
    75. Nahvi RJ, Nwokafor C, Serova LI, Sabban EL. Single prolonged stress as a prospective model for posttraumatic stress disorder in females. Front Behav Neurosci. 2019;13:17. doi: 10.3389/fnbeh.2019.00017
    76. Judkins JL, Moore BA, Collette TL, Hale WJ, Peterson AL, Morissette SB. Incidence rates of posttraumatic stress disorder over a 17-year period in active duty military service members. J Trauma Stress. 2020;33(6):994-1006. doi: 10.1002/jts.22558
    77. Merians AN, Gross G, Spoont MR, Bellamy CD, Harpaz-Rotem I, Pietrzak RH. Racial and ethnic mental health disparities in U.S. military veterans: results from the National Health and Resilience in Veterans Study. J Psychiatr Res. 2023;161:71-76. doi: 10.1016/j.jpsychires.2023.03.005
    78. Zhou Z, Zhu G, Hariri AR, et al. Genetic variation in human NPY expression affects stress response and emotion. Nature. 2008;452(7190):997-1001. doi: 10.1038/nature06858
    79. Sommer WH, Lidström J, Sun H, et al. Human NPY promoter variation rs16147:T>C as a moderator of prefrontal NPY gene expression and negative affect. Hum Mutat. 2010;31(8):E1594-E1608. doi: 10.1002/humu.21299
    80. Chang HA, Fang WH, Chang TC, Huang SY, Chang CC. Association of neuropeptide Y promoter polymorphism rs16147 with perceived stress and cardiac vagal outflow in humans. Sci Rep. 2016;6(1):31683. doi: 10.1038/srep31683
    81. Watkins LE, Han S, Krystal JH, Southwick SM, Gelernter J, Pietrzak RH. Association between functional polymorphism in neuropeptide Y gene promoter rs16147 and resilience to traumatic stress in US military veterans. J Clin Psychiatry. 2017;78(8):e1058-e1059. doi: 10.4088/JCP.17l11646
    82. Schmeltzer SN, Herman JP, Sah R. Neuropeptide Y (NPY) and posttraumatic stress disorder (PTSD): a translational update. Exp Neurol. 2016;284(Pt B):196-210. doi: 10.1016/j.expneurol.2016.06.020
    83. Xue Y, Taub PR, Iqbal N, et al. Cardiac biomarkers, mortality, and post-traumatic stress disorder in military veterans. Am J Cardiol. 2012;109(8):1215-1218. doi: 10.1016/j.amjcard.2011.11.063
    84. Tang J, Liu C, Wang Z, et al. Neuropeptide Y as a prognostic biomarker in electrical storm. JACC Clin Electrophysiol. 2025;11(4):655-663. doi: 10.1016/j.jacep.2024.11.021
    85. Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. Front Public Health. 2017;5:258. doi: 10.3389/fpubh.2017.00258
    86. Thayer JF, Lane RD. Claude Bernard and the heart–brain connection: further elaboration of a model of neurovisceral integration. Neurosci Biobehav Rev. 2009;33(2):81-88. doi: 10.1016/j.neubiorev.2008.08.004
    87. Geracioti TD Jr, Baker DG, Ekhator NN, et al. CSF norepinephrine concentrations in posttraumatic stress disorder. Am J Psychiatry. 2001;158(8):1227-1230. doi: 10.1176/appi.ajp.158.8.1227
    88. Tan G, Dao TK, Farmer L, Sutherland RJ, Gevirtz R. Heart rate variability (HRV) and posttraumatic stress disorder (PTSD): a pilot study. Appl Psychophysiol Biofeedback. 2011;36(1):27-35. doi: 10.1007/s10484-010-9141-y
    89. Pyne JM, Constans JI, Nanney JT, et al. Heart rate variability and cognitive bias feedback interventions to prevent post-deployment PTSD: results from a randomized controlled trial. Mil Med. 2019;184(1–2):e124-e132. doi: 10.1093/milmed/usy171
    90. Schuman DL, Lawrence KA, Boggero I, et al. A pilot study of a three-session heart rate variability biofeedback intervention for veterans with posttraumatic stress disorder. Appl Psychophysiol Biofeedback. 2023;48(1):51-65. doi: 10.1007/s10484-022-09565-z
    91. Polak AR, Witteveen AB, Denys D, Olff M. Breathing biofeedback as an adjunct to exposure in cognitive behavioral therapy hastens the reduction of PTSD symptoms: a pilot study. Appl Psychophysiol Biofeedback. 2015;40(1):25-31. doi: 10.1007/s10484-015-9268-y
    92. Rae Olmsted KL, Bartoszek M, Mulvaney S, et al. Effect of stellate ganglion block treatment on posttraumatic stress disorder symptoms: a randomized clinical trial. JAMA Psychiatry. 2020;77(2):130-138. doi: 10.1001/jamapsychiatry.2019.3474
    93. Capilupi MJ, Kerath SM, Becker LB. Vagus nerve stimulation and the cardiovascular system. Cold Spring Harb Perspect Med. 2020;10(2):a034173. doi: 10.1101/cshperspect.a034173
    94. Serova LI, Mulhall H, Sabban E. NPY1 receptor agonist modulates development of PTSD-like behaviors in rats. Front Neurosci. 2017;11:203. doi: 10.3389/fnins.2017.00203
    95. Haensel A, Mills PJ, Nelesen RA, Ziegler MG, Dimsdale JE. The relationship between heart rate variability and inflammatory markers in cardiovascular diseases. Psychoneuroendocrinology. 2008;33(10):1305-1312. doi: 10.1016/j.psyneuen.2008.08.007
    96. Cooper TM, McKinley PS, Seeman TE, Choo TH, Lee S, Sloan RP. Heart rate variability predicts levels of inflammatory markers: evidence for the vagal anti-inflammatory pathway. Brain Behav Immun. 2015;49:94-100. doi: 10.1016/j.bbi.2014.12.017
    97. Passos IC, Vasconcelos-Moreno MP, Costa LG, et al. Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry. 2015;2(11):1002-1012. doi: 10.1016/S2215-0366(15)00309-0
    98. Guichard L, An X, Neylan TC, et al. Heart rate variability wrist-wearable biomarkers identify adverse posttraumatic neuropsychiatric sequelae after traumatic stress exposure. Psychiatry Res. 2024;342:116260. doi: 10.1016/j.psychres.2024.116260
    99. Baker DG, Nash W, Litz B, Geyer M, Risbrough V, Nievergelt C. Predictors of risk and resilience for posttraumatic stress disorder among ground combat Marines: methods of the Marine Resiliency Study. Prev Chronic Dis. 2012;9:E97. doi: 10.5888/pcd9.110134
    100. Eraly SA, Nievergelt CM, Maihofer AX, et al. Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. JAMA Psychiatry. 2014;71(4):423-431. doi: 10.1001/jamapsychiatry.2013.4374
    101. Glatt SJ, Tylee DS, Chandler SD, et al. Blood-based gene-expression predictors of PTSD risk and resilience among deployed Marines: a pilot study. Am J Med Genet B Neuropsychiatr Genet. 2013;162(4):313-326. doi: 10.1002/ajmg.b.32167
    102. Tylee DS, Chandler SD, Nievergelt CM, et al. Blood-based gene-expression biomarkers of post-traumatic stress disorder among deployed Marines: a pilot study. Psychoneuroendocrinology. 2015;51:472-494. doi: 10.1016/j.psyneuen.2014.09.024
    103. Zhang L, Hu XZ, Li X, et al. Potential chemokine biomarkers associated with PTSD onset, risk and resilience as well as stress responses in US military service members. Transl Psychiatry. 2020;10(1):31. doi: 10.1038/s41398-020-0693-1
    104. Schultebraucks K, Qian M, Abu-Amara D, et al. Pre-deployment risk factors for PTSD in active-duty personnel deployed to Afghanistan: a machine-learning approach for analyzing multivariate predictors. Mol Psychiatry. 2021;26(9):5011-5022. doi: 10.1038/s41380-020-0789-2
    105. van Zuiden M, Geuze E, Willemen HLDM, et al. Pre-existing high glucocorticoid receptor number predicting development of posttraumatic stress symptoms after military deployment. Am J Psychiatry. 2011;168(1):89-96. doi: 10.1176/appi.ajp.2010.10050706
    106. van Zuiden M, Geuze E, Willemen HLDM, et al. Glucocorticoid receptor pathway components predict posttraumatic stress disorder symptom development: a prospective study. Biol Psychiatry. 2012;71(4):309-316. doi: 10.1016/j.biopsych.2011.10.026
    107. López-Buenafe GDR, Alonso-Cabrera JA, Marcuello C, et al. Fabrication and characterization of PEDOT:PSS-based microstructured electrodes for in vitro cell culture. Adv Mater Interfaces. 2025;12(20):2500097. doi: 10.1002/admi.202500097
    108. Yuan Q, Qin C, Xu D, et al. PEDOT:PSS-modified organic flexible and implantable microelectrode for internal bi-directional electrophysiology of three-dimensional cardiomyocyte spheroid. ACS Sens. 2025;10(1):460-469. doi: 10.1021/acssensors.4c02755
    109. Cornuéjols R, Ivanov A, Ghestem A, et al. Flexible depth probes with PEDOT:PSS microelectrodes for chronic recording and stimulation. ACS Appl Mater Interfaces. 2025;17(29):42148-42161. doi: 10.1021/acsami.5c02872
Next article in this issue
Share
Back to top
Brain & Heart, Electronic ISSN: 2972-4139 Published by AccScience Publishing
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here
Accept